Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed

PURPOSE: Patients with advanced pancreatic adenocarcinoma have a poor prognosis and limited second-line treatment options. Evidence suggests a role for the Janus kinase (JAK)/signal transducer and activator of transcription pathway in the pathogenesis and clinical course of pancreatic cancer. PATIEN...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: Hurwitz, Herbert I., Uppal, Nikhil, Wagner, Stephanie A., Bendell, Johanna C., Beck, J. Thaddeus, Wade, Seaborn M., Nemunaitis, John J., Stella, Philip J., Pipas, J. Marc, Wainberg, Zev A., Manges, Robert, Garrett, William M., Hunter, Deborah S., Clark, Jason, Leopold, Lance, Sandor, Victor, Levy, Richard S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2015
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5089161/
https://ncbi.nlm.nih.gov/pubmed/26351344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.61.4578
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller